Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524313 | 0.81 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK14 | |
| SCHEMBL22768040 | 0.75 | ALDH1A1 (0.39) | CSNK1DACVR1 | |
| SCHEMBL26720295 | 0.75 | GRM2 (0.45) | CSNK1DMAPK14 | |
| SCHEMBL26720231 | 0.74 | CSNK1D (0.57) | CSNK1DCSNK1EMAPK14ATRATRIP | |
| SCHEMBL25220259 | 0.74 | MAPK14 (0.46) | CSNK1DCSNK1EMAPK14 | |
| SCHEMBL26720293 | 0.73 | SLC2A1 (0.39) | CSNK1D | |
| SCHEMBL29513324 | 0.72 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14ATRATRIP | |
| SCHEMBL26720865 | 0.72 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14ATRATRIP | |
| SCHEMBL26720871 | 0.71 | CSNK1D (0.51) | CYP11B2CYP11B1CSNK1DCSNK1EMAPK14 | |
| SCHEMBL17382679 | 0.65 | CSNK1D (0.48) | CSNK1DCSNK1EMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214214-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | CYP11B2 3186/4885CYP11B1 2399/4885CSNK1D 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.